Lars Wallentin

1.3k total citations
13 papers, 983 citations indexed

About

Lars Wallentin is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Lars Wallentin has authored 13 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 5 papers in Surgery and 5 papers in Internal Medicine. Recurrent topics in Lars Wallentin's work include Acute Myocardial Infarction Research (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Lars Wallentin is often cited by papers focused on Acute Myocardial Infarction Research (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Lars Wallentin collaborates with scholars based in Sweden, United States and Australia. Lars Wallentin's co-authors include Eva Swahn, Oscar Ö. Braun, Agneta Siegbahn, David Erlinge, Kenneth J. Winters, Stefan James, Atsuhiro Sugidachi, Christoph Varenhorst, Joseph A. Jakubowski and Tim Allhoff and has published in prestigious journals such as Circulation, European Heart Journal and The American Journal of Cardiology.

In The Last Decade

Lars Wallentin

13 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Wallentin Sweden 8 813 352 299 171 126 13 983
Elizabeth Tarka United States 10 185 0.2× 163 0.5× 38 0.1× 99 0.6× 87 0.7× 16 442
Hafid Narayan United Kingdom 14 325 0.4× 137 0.4× 24 0.1× 38 0.2× 39 0.3× 21 611
B Chin United Kingdom 10 587 0.7× 55 0.2× 279 0.9× 12 0.1× 25 0.2× 15 787
Jacek Godlewski Poland 9 290 0.4× 128 0.4× 66 0.2× 14 0.1× 41 0.3× 18 611
Marie‐Laure Ozoux France 10 333 0.4× 151 0.4× 301 1.0× 9 0.1× 27 0.2× 18 581
D. Hatseras Greece 15 304 0.4× 133 0.4× 39 0.1× 15 0.1× 55 0.4× 23 603
Sarah Sloan United States 12 561 0.7× 324 0.9× 28 0.1× 42 0.2× 19 0.2× 21 843
Saman Rasoul Netherlands 17 777 1.0× 420 1.2× 37 0.1× 23 0.1× 13 0.1× 57 1.0k
Jeffrey S. Riesmeyer United States 12 385 0.5× 329 0.9× 74 0.2× 7 0.0× 63 0.5× 23 717
J R Hangartner United Kingdom 6 525 0.6× 390 1.1× 66 0.2× 6 0.0× 25 0.2× 6 809

Countries citing papers authored by Lars Wallentin

Since Specialization
Citations

This map shows the geographic impact of Lars Wallentin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Wallentin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Wallentin more than expected).

Fields of papers citing papers by Lars Wallentin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Wallentin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Wallentin. The network helps show where Lars Wallentin may publish in the future.

Co-authorship network of co-authors of Lars Wallentin

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Wallentin. A scholar is included among the top collaborators of Lars Wallentin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Wallentin. Lars Wallentin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Leonardi, Sergio, Pierluigi Tricoci, HD White, et al.. (2013). Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial. European Heart Journal. 34(23). 1723–1731. 31 indexed citations
2.
Zhu, Jun, Lisheng Liu, Byung‐Hee Oh, et al.. (2013). Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia. European Heart Journal. 34(suppl 1). P5613–P5613. 4 indexed citations
3.
4.
5.
Janzon, Magnus, Martin Henriksson, L. Scott Levin, et al.. (2010). Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns. 1 indexed citations
6.
James, Stefan, John T. Brandt, Joseph A. Jakubowski, et al.. (2008). Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thrombosis and Haemostasis. 100(10). 626–633. 59 indexed citations
7.
Kempf, Tibor, E. Bjorklund, S.‐O. Olofsson, et al.. (2007). Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. European Heart Journal. 28(23). 2858–2865. 189 indexed citations
8.
9.
Ottervanger, Jan Paul, Paul W. Armstrong, Eric Boersma, et al.. (2004). Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. European Heart Journal. 25(17). 1494–1501. 29 indexed citations
10.
11.
Wallentin, Lars. (2000). Long-term management-The way forward?. Clinical Cardiology. 23(S1). 13–17. 3 indexed citations
12.
Wallentin, Lars. (2000). Low molecular weight heparin in unstable coronary artery disease. Expert Opinion on Investigational Drugs. 9(3). 581–592. 7 indexed citations
13.
Swahn, Eva & Lars Wallentin. (1997). Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC). The American Journal of Cardiology. 80(5). 25E–29E. 264 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Tarka Breakdown of academic impact, for papers by Hafid Narayan Breakdown of academic impact, for papers by B Chin Breakdown of academic impact, for papers by Jacek Godlewski Breakdown of academic impact, for papers by Marie‐Laure Ozoux Breakdown of academic impact, for papers by D. Hatseras Breakdown of academic impact, for papers by Sarah Sloan Breakdown of academic impact, for papers by Saman Rasoul Breakdown of academic impact, for papers by Jeffrey S. Riesmeyer Breakdown of academic impact, for papers by J R Hangartner
Rankless by CCL
2026